# A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

> **NCT06797869** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 142 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Diabetic Peripheral Neuropathy

## Interventions

- **DRUG:** CagriSema (Cagrilintide B and Semaglutide I)
- **DRUG:** Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)

## Key facts

- **NCT ID:** NCT06797869
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-29
- **Primary completion:** 2026-08-21
- **Final completion:** 2026-08-21
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06797869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06797869, "A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06797869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*